Ziccum
Ziccum AB (publ) is a biotechnology company specializing in innovative drying and formulation technologies for biologics and vaccines. Their proprietary technology, LaminarPace, enables the transformation of delicate liquid biologics into robust, thermostable dry powders, facilitating easier storage, transport, and administration. The company is actively engaged in research collaborations, project development, and industry partnerships to advance next-generation biologics and mRNA therapeutics, aiming to revolutionize drug delivery and biologics stability.
Industries
Nr. of Employees
small (1-50)
Products
Ambient mass-transfer drying platform (development prototypes and models)
A platform concept consisting of equipment prototypes and process models for ambient mass-transfer drying to convert biologics into stable dry powders suitable for alternative delivery routes and reduced cold-chain dependence.
Ambient mass-transfer drying platform (development prototypes and models)
A platform concept consisting of equipment prototypes and process models for ambient mass-transfer drying to convert biologics into stable dry powders suitable for alternative delivery routes and reduced cold-chain dependence.
Services
Contracted evaluation of partner mRNA/LNP or biologic materials to generate technical data on stability, activity and suitability for dry‑powder formats.
Long-term agreements with GMP equipment specialists to support industrialisation and progression to GMP-capable manufacturing of dried biologic products.
Development of detailed 3D and dynamic process models to support understanding, optimisation and transfer of drying operations to industrial partners; includes collaboration with academic partners and funded modelling projects.
Design and delivery of engineering prototype systems for separation and collection of dried powders aimed at enabling continuous downstream processing.
Coordination and development support for nebulizer/mechatronic aerosol components to enable nebulization and aerosol delivery as part of the drying and formulation workflow.
Contracted evaluation of partner mRNA/LNP or biologic materials to generate technical data on stability, activity and suitability for dry‑powder formats.
Long-term agreements with GMP equipment specialists to support industrialisation and progression to GMP-capable manufacturing of dried biologic products.
Development of detailed 3D and dynamic process models to support understanding, optimisation and transfer of drying operations to industrial partners; includes collaboration with academic partners and funded modelling projects.
Design and delivery of engineering prototype systems for separation and collection of dried powders aimed at enabling continuous downstream processing.
Coordination and development support for nebulizer/mechatronic aerosol components to enable nebulization and aerosol delivery as part of the drying and formulation workflow.
Expertise Areas
- Formulation and drying of biologics including mRNA/LNP
- Ambient mass-transfer drying and dry-powder stabilisation
- Particle engineering for inhalation delivery
- Nebulization and aerosol generation for biologics
Key Technologies
- Ambient mass-transfer drying
- Dry-powder formulation for mRNA/LNP
- Particle engineering for inhalation
- Continuous powder processing
News & Updates
Participation in Europe’s leading life science partnering event to showcase LaminarPace technology.
Highlighting the disruptive potential of LaminarPace technology to investors and industry leaders.
The technology is recognized for its innovative approach to vaccine stabilization.
Industry articles highlight Ziccum’s innovative approach to biologics stabilization and delivery.
Official registration of Ziccum’s proprietary technology LaminarPace with the USPTO.
Participation in Europe’s leading life science partnering event to showcase LaminarPace technology.
Highlighting the disruptive potential of LaminarPace technology to investors and industry leaders.
The technology is recognized for its innovative approach to vaccine stabilization.
Industry articles highlight Ziccum’s innovative approach to biologics stabilization and delivery.
Official registration of Ziccum’s proprietary technology LaminarPace with the USPTO.